Articolul precedent |
Articolul urmator |
295 2 |
Ultima descărcare din IBN: 2024-03-31 23:05 |
SM ISO690:2012 BURSACOVSCHI, Daniela, CAZACU, Janna, LÎSÎI, Dorin, VATAMAN, Eleonora. Impact of non-cardiac comorbidities on heart failure outcomes in patients after coronary revascularization therapy. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 124. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | |||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | |||||||
|
|||||||
Pag. 124-124 | |||||||
|
|||||||
Descarcă PDF | |||||||
Rezumat | |||||||
Background. Heart failure (HF) and non-cardiac comorbidities often coexist. However, the prevalence and prognostic impact of non-cardiac comorbidities on the hospitalization rates and all-cause mortality according to the two phenotypes of HF remain inadequately studied. Objective of the study. To analyze the impact of 15 non-cardiac comorbidities on hospitalization rate and all-cause mortality and their interaction with EF. Material and Methods. A 48 months prospective observational study enrolled 166 patients. They underwent coronary artery bypass grafting, percutaneous coronary angioplasty and previously where admitted to the cardiac rehabilitation department and correlated to the association of non-cardiac comorbidities in particular EF phenotypes. HFmrEF defined as EF from 40-49% and HFpEF as EF ≥ 50%. Results. HFmrEF patients had a similar clinical profile to that of HFpEF patients in terms of age, body mass index and blood pressure (p<0,001). The HFmrEF and HFpEF groups had similar re-hospitalization rates and all-cause mortality (p<0,001). From non-cardiac comorbidities, a greater impact on hospital re-admission was seen through obstructive bronchopulmonary diseases OR 1.60 95% CI 0.50 – 0.73 and 1.62 95% CI 0.5 – 0.75 (p<0,05), thyroid gland diseases OR 1.40 95% CI 0.70 – 0.95 and 1.35 95% CI 0.68 – 0.95 (p<0,01) and ischemic stroke OR 2.1 95% CI 0.42 – 0.60 and 2.1 95% CI 0.40 – 0.63 (p<0,05). Conclusion. Non-cardiac comorbidities contribute both to mortality and to hospital re-admissions, thus, we determined the importance of including the management of comorbidities as a part of heart failure treatment in both patient categories. |
|||||||
Cuvinte-cheie heart failure, comorbidities, ejection fraction, insuficienţă cardiacă, comorbidități, fracția de ejecție |
|||||||
|